Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 5
2013 6
2014 6
2015 2
2016 9
2017 9
2018 10
2019 17
2020 27
2021 28
2022 27
2023 32
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron-results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP).
Hopff SM, Appel KS, Miljukov O, Schneider J, Addo MM, Bals R, Bercker S, Blaschke S, Bröhl I, Büchner N, Dashti H, Erber J, Friedrichs A, Geisler R, Göpel S, Hagen M, Hanses F, Jensen BO, Keul M, Krawczyk A, Lorenz-Depiereux B, Meybohm P, Milovanovic M, Mitrov L, Nürnberger C, Obst W, Römmele C, Schäfer C, Scheer C, Scherer M, Schmidt J, Seibel K, Sikdar S, Tebbe JJ, Tepasse PR, Thelen P, Vehreschild MJGT, Weismantel C, Vehreschild JJ. Hopff SM, et al. Among authors: vehreschild mjgt. Infection. 2024 May 3. doi: 10.1007/s15010-024-02270-5. Online ahead of print. Infection. 2024. PMID: 38700656
Vaccine-derived yellow fever in an immunocompromised patient on anti-CD20-antibody therapy and its treatment with sofosbuvir.
Weirauch T, Burger G, Cadar D, Gabriel M, Koepsell J, Schüttfort G, de Leuw P, Bickel M, Vehreschild MJGT, Wolf T, Wetzstein N. Weirauch T, et al. Among authors: vehreschild mjgt. Int J Infect Dis. 2024 Mar 21;143:107017. doi: 10.1016/j.ijid.2024.107017. Online ahead of print. Int J Infect Dis. 2024. PMID: 38521450 Free article.
The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registries.
Hasseli R, Hanses F, Stecher M, Specker C, Weise T, Borgmann S, Hasselberger M, Hertenstein B, Hower M, Hoyer BF, Koll C, Krause A, von Lilienfeld-Toal M, Lorenz HM, Merle U, Nunes de Miranda SM, Pletz MW, Regierer AC, Richter JG, Rieg S, Roemmele C, Ruethrich MM, Schmeiser T, Schulze-Koops H, Strangfeld A, Vehreschild MJGT, Voit F, Voll RE, Vehreschild JJ, Müller-Ladner U, Pfeil A. Hasseli R, et al. Among authors: vehreschild mjgt. Front Med (Lausanne). 2024 Mar 6;11:1332716. doi: 10.3389/fmed.2024.1332716. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38510457 Free PMC article.
Quality, availability and suitability of antimicrobial stewardship guidance: a multinational qualitative study.
Linde-Ozola Z, Classen AY, Giske CG, Göpel S, Eliakim-Raz N, Semret M, Simonsen GS, Vehreschild JJ, Jørgensen SB, Kessel J, Kleppe LKS, Oma DH, Vehreschild MJGT, Vilde A, Dumpis U; PILGRIM study group. Linde-Ozola Z, et al. Among authors: vehreschild mjgt. JAC Antimicrob Resist. 2024 Mar 14;6(2):dlae039. doi: 10.1093/jacamr/dlae039. eCollection 2024 Apr. JAC Antimicrob Resist. 2024. PMID: 38486662 Free PMC article.
Prevalence of infectious diseases, immunity to vaccine-preventable diseases and chronic medical conditions among Ukrainian refugees in Germany - A cross sectional study from the German Network University Medicine (NUM).
Brinkmann F, Friedrichs A, Behrens GM, Behrens P, Berner R, Caliebe A, Denkinger CM, Giesbrecht K, Gussew A, Hoffmann AT, Hojenski L, Hovardovska O, Dopfer-Jablonka A, Kaasch AJ, Kobbe R, Kraus M, Lindner A, Maier C, Mitrov L, Nauck M, de Miranda SN, Scherer M, Schmiedel Y, Stahl D, Timmesfeld N, Toepfner N, Vehreschild J, Wohlgemuth WA, Petersmann A, Vehreschild MJGT; NU(M)KRAINE Study Group. Brinkmann F, et al. Among authors: vehreschild mjgt. J Infect Public Health. 2024 Apr;17(4):642-649. doi: 10.1016/j.jiph.2024.02.003. Epub 2024 Feb 16. J Infect Public Health. 2024. PMID: 38458134 Free article.
Regulatory workshop on challenge strain development and GMP manufacture - A stakeholder meeting report.
Corti N, Chiu C, Cox RJ, Demont C, Devaster JM, Engelhardt OG, Gorringe A, Hassan K, Hoefnagel M, Kamerling I, Krut O, Lane C, Liebers R, Luke C, Van Molle W, Morel S, Neels P, Roestenberg M, Rubbrecht M, Klaas Smits W, Stoughton D, Talaat K, Vehreschild MJGT, Wildfire A, Meln I, Olesen OF. Corti N, et al. Among authors: vehreschild mjgt. Biologicals. 2024 Feb;85:101746. doi: 10.1016/j.biologicals.2024.101746. Epub 2024 Feb 3. Biologicals. 2024. PMID: 38309984 Free article.
TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.
Tsakmaklis A, Farowski F, Zenner R, Lesker TR, Strowig T, Schlößer H, Lehmann J, von Bergwelt-Baildon M, Mauch C, Schlaak M, Knuever J, Schweinsberg V, Heinzerling LM, Vehreschild MJGT. Tsakmaklis A, et al. Among authors: vehreschild mjgt. BMC Cancer. 2023 Nov 28;23(1):1160. doi: 10.1186/s12885-023-11551-5. BMC Cancer. 2023. PMID: 38017389 Free PMC article.
164 results